ArticleVaccines2020

Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.

Artem P Tkachuk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.